Top 10 Medical Stocks To Invest In Right Now

Marijuana is well on its way to becoming the “norm” in modern America.

Eight states – Alaska, California, Colorado, Maine, Maryland, Massachusetts, Oregon, and Washington – and the District of Columbia have fully legalized possession of small amounts of marijuana for adults’ recreational use. An additional 13 states have decriminalized it. And 29 states, along with Puerto Rico and Guam, now allow the use of medical marijuana.

However, the drug is still classified as an illegal Schedule I substance in the eyes of the federal government.

Top 10 Medical Stocks To Invest In Right Now: WGL Holdings Inc(WGL)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Brean Capital reported on Friday that it has upgraded natural gas utility company WGL Holdings Inc (WGL).

    The firm has raised its rating on WGL from “Hold” to “Buy,” and has given the company a $46 price target. This price target suggests a 12% increase from the stock’s current price of $40.62. The upgrade was primarily based on valuation and future investment opportunities.

    “Like many utilities in the gas LDC space, the shares of WGL Holdings have come off recent highs and are now trading at a level we consider attractive,” analyst Michael Gaugler comments. “Beyond valuation, we consider the recent announcement of conditional approval of Dominion’s Cove Point facility for LNG export as a positive development in terms of future investment opportunities, given the company’s one-third interest in the Commonwealth Pipeline project, which we believe will be revisited due to future increased demand.”

    WGL Holdings shares were mostly flat during pre-market trading Friday. The stock has been mostly flat YTD.

Top 10 Medical Stocks To Invest In Right Now: Dover Corporation(DOV)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Dover Corp. (NYSE: DOV) was at $75.19 at the end of 2016 and the firm has a $85.00 price objective. This is 13% in implied upside for Dover, before considering its 2.3% dividend yield.

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Tuesday was Dover Corp. (NYSE: DOV) which rose about 4% to $103.82. The stocks 52-week range is $76.23 to $109.06. Volume was 4.7 million compared to the daily average volume of 1.1 million.

Top 10 Medical Stocks To Invest In Right Now: 3M Company(MMM)

Advisors’ Opinion:

  • [By WWW.THESTREET.COM]

    Who are the likely candidates for the next round of upgrades? Cramer said he’s betting that 3M (MMM) will be in the mix, along with Walmart (WMT) and especially Home Depot (HD) , which should have a strong spring planting season with good comparisons to last year. Investors might also see upgrades on Honeywell (HON) and Nike (NKE) , Cramer suggested.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 1.51% at $235.69. The stock’s 52-week range is $185.71 to $259.77. Volume was around 1.6 million shares, about a third below the daily average of about 2.4 million. The company had no specific news Thursday.

  • [By Paul Ausick]

    The DJIA stock posting the largest daily percentage gain ahead of the close Monday was 3M Company (NYSE: MMM) which traded up 3.23% at $244.68. The stock’s 52-week range is $86.31 to $259.77. Volume was about 25% lower than the daily average of around 2.4 million. The company had no specific news Monday.

  • [By Chris Lange]

    3M Company (NYSE: MMM) is set to report its second-quarter results on Tuesday. The analysts consensus estimates call for EPS of $2.54 and $7.86 billion in revenue. Shares of 3M were changing hands at $211.07 at Fridays close. The consensus price target is $205.09, and the 52-week range is $163.85 to $214.57.

  • [By Paul Ausick]

    3M Company (NYSE: MMM) traded up 1.38% at $198.50. The stock’s 52-week range is $163.85 to $199.90. Volume was about 35% lower than the daily average of around 1.9 million shares. The company had no specific news Monday.

  • [By Keith Fitz-Gerald]

    First, the Dow dropped below 19,800 points with two stocks – The Goldman Sachs Group Inc. (NYSE:GS) and 3M Company (NYSE:MMM) – experiencing a $3.26 billion selloff alone. Big banking stocks including Wells Fargo & Company (NYSE:WFC) and JPMorgan Chase and Co. (NYSE:JPM) sold off far more severely than the S&P 500 itself. Tech stocks were more or less unscathed, with the exception of Alphabet Inc. (NasdaqGS:GOOG), which received a 2.55% buzzcut of $26 per share.

Top 10 Medical Stocks To Invest In Right Now: iShares US Basic Materials (IYM)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows shares of small cap Apogee Enterprises strongly outperforming potential performancebenchmarks like theMaterials Select Sector SPDR (NYSEARCA: XLB) and iShares Dow Jones US Basic Materials ETF (NYSEARCA: IYM) albeit that performance has fallen off:

Top 10 Medical Stocks To Invest In Right Now: DAVIDsTEA Inc.(DTEA)

Advisors’ Opinion:

  • [By Monica Gerson]

    DavidsTea Inc (NASDAQ: DTEA) is expected to post its quarterly earnings at $0.43 per share on revenue of $71.74 million.

    SemiLEDs Corporation (NASDAQ: LEDS) is estimated to post its quarterly earnings.

Top 10 Medical Stocks To Invest In Right Now: Alexion Pharmaceuticals, Inc.(ALXN)

Advisors’ Opinion:

  • [By David Sterman]

    Growth-oriented investors should also check out Alexion Pharmaceuticals (Nasdaq: ALXN(link is external)), which falls through the cracks between the massive well-established biotechs, and the small-cap biotechs that are still pre-revenue.

    Alexion targets rare and severe diseases, and has built a broad platform of drugs to treat them. Sales growth has never been less than 37% at any point in the past eight years, and 20% to 25% growth appears locked in over coming years as well. Analysts at UBS, who see 30% upside to their $202 price target, believe that a healthy drug pipeline provides multiple catalysts this year in the form of clinical trial updates. They suggest that shares would be worth $230 in a buyout scenario. 

  • [By Ben Levisohn]

    Alexion Pharmaceuticals (ALXN) tumbled to the bottom of the S&P 500 today after the company’s CEO and CFO left the firm following the delay of its 10-Q last month.

    Getty Images

    Alexion Pharmaceuticals dropped 13% to $115.04 today, while the S&P 500 dipped 0.1% to 2,256.96.

    BMO’s M. Ian Somaiya offers his take on the chaos at Alexion:

    Alexion has delayed its 3Q 10-Q filing as a result of an internal investigation involving the company’s sales practices. The company continues to believe restatement of previously reported results is not required.Alexion expects filing of 3Q 10-Q in January 2017 or earlier, and 4Q/FY2016 earnings in February, when guidance is expected.

    Near-term downside may be priced in, caution on guidance. We believe the announcement of new management adds a new overhang to the stock, but also believe downside may be priced in (Alexion is down ~9% at open) and may provide an opportunity for investors to dip their toes if not their feet. We believe Alexion’s recovery will be driven by its next-generation C5 inhibitor, ALXN-1210, as every-eight-week dosing should enable Alexion to maintain 75% of the PNH market, while SubQ success, depending on dosing schedule/volume, may enable Alexion to do better. Additionally, we believe label extensions for Soliris in rMG, NMO may provide near-term growth drivers. Further upside is dependent on 30 pre-clinical assets in Alexion’s pipeline and the pace of Soliris adoption in MG. We believe the weakness may provide a unique opportunity for accumulation, with potential downside risk related to guidance from new management during 4Q/FY2016 earnings in February.

    Alexion Pharmaceuticals’ market capitalization fell to $25.8 billion today from $29.6 billion yesterday. It reported net income of $144 million on sales of $2.5 billion in 2015.

  • [By Chris Lange]

    Alexion Pharmaceuticals Inc.s (NASDAQ: ALXN) short interest decreased to 4.33 million, compared to the previous level of 4.98 million. Shares closed most recently at $118.83, in a 52-week range of $110.56 to $193.45.

  • [By Lisa Levin] Related Chardan Analyst Suggests An AveXis-Ionis Pair Trade Why The Biogen-Ionis News Is A Boon For AveXis AveXis' (AVXS) CEO Sean Nolan on Q4 2016 Results – Earnings Call Transcript (Seeking Alpha)
    Related CLBS Earnings Scheduled For March 17, 2017 15 Biggest Mid-Day Gainers For Thursday Caladrius Biosciences beats by $0.07, beats on revenue (Seeking Alpha) Gainers
    Caladrius Biosciences Inc (NASDAQ: CLBS) shares rose 20.2 percent to $6.13 in pre-market trading after the company reported a narrower-than-expected quarterly loss.
    Arbutus Biopharma Corp (NASDAQ: ABUS) rose 12.3 percent to $3.20 in pre-market trading after the company disclosed that it has licensed LNP delivery technology to Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for use in single messenger RNA product candidate.
    AveXis Inc (NASDAQ: AVXS) rose 12.2 percent to $81.66 in pre-market trading after the company reported topline data from Phase 1 trial of AVXS-101.
    TOP SHIPS Inc (NASDAQ: TOPS) shares rose 10.5 percent to $2.43 in pre-market trading after surging 109.52 percent on Thursday.
    ChipMOS TECHNOLOGIES INC. (NASDAQ: IMOS) rose 9.8 percent to $17.45 in pre-market trading after declining 0.44 percent on Thursday.
    Sino-Global Shipping America, Ltd. (NASDAQ: SINO) rose 8.3 percent to $3.38 in pre-market trading after climbing 23.81 percent on Thursday.
    Diana Containerships Inc (NASDAQ: DCIX) rose 7.6 percent to $2.99 in pre-market trading after surging 12.55 percent on Thursday.
    Steel Dynamics, Inc. (NASDAQ: STLD) rose 5.2 percent to $37.25 in pre-market trading. Steel Dynamics expects Q1 earnings of $0.77 to $0.81 per diluted share. The company also declared a quarterly cash dividend of $0.1550 per common share.
    Adobe Systems Incorporated (NASDAQ: ADBE)
  • [By Paul Ausick]

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) posted a new 52-week low of $102.47 on Tuesday, down more than 11% compared with Monday’s closing price of $115.42. The stock’s 52-week high is $157.02. Volume totaled more than 16 million shares, nearly 6 times the daily average of about 3 million. The company announced several executive changes this morning.

Top 10 Medical Stocks To Invest In Right Now: athenahealth, Inc.(ATHN)

Advisors’ Opinion:

  • [By ]

    Under a single-payer system, healthcare becomes a regulated utility much like electricity with just a few large, best-in-class players. Athenahealth (Nasdaq: ATHN) could combine with Walgreen Boots Alliance (NYSE: WBA). Maybe each monolith will cover a specific region like Southern Company (NYSE: SO) and Consolidated Edison (NYSE: ED).

  • [By Dan Caplinger]

    Meanwhile, earnings season continued to play out, and although the technology industry saw some extremely encouraging reports, not all stocks participated in the rally. Athenahealth (NASDAQ:ATHN), Synchrony Financial (NYSE:SYF), and Time (NYSE:TIME) were among the worst performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so poorly.

  • [By WWW.THESTREET.COM]

    Shares of Athena Health (ATHN) are up 37% in just over a month. Is there still more room to run?

    Cramer said for years Athena had been a fast-growing stock, but as the company transitioned from growth to profitability, things began to get ugly. The company’s bombastic CEO, and his “colorful” personality began to rub shareholders the wrong way.

  • [By Ben Levisohn]

    Athenahealth (ATHN) last night announced that its CFO and administrative chief, Kristi Matus, would be leaving the company. Her departure has not been embraced by investors, who have pushed shares lower today. Leerink’s David Larsen understands their concerns:

    In our view, the CFO departure may be indicative of internal operational challenges. We still think it is possible that Kristi Matus is seeking an environment that is not as demanding as ATHN, though this has not been confirmed by management. Management harped on the point that bifurcation is part of the strategic initiative of ATHN to reenergize the culture of the company, and Jonathan Bush noted how he himself hopes to spend more time on talent and culture and less time on entering new markets and building new products.

    We continue to believe that ATHN is facing challenges. We continue to believe the market is fundamentally slowing and bookings growth may become more lumpy as we progress through 2016. We still believe there will be a slow-down in the bookings growth rate b/c of a possible slow-down in the ambulatory EMR market and the fact that we are in the final payment year of Meaningful Use. Much of the call focused on Kristi Matus’s departure as a major loss for the company of a leader who was “masterful with investors.” According to management, the decision to split the CFO and CFAO responsibilities was not a reflection of her ability.

    Baird’s Matthew Gillmor and Sean McBride are less worried:

    The unexpected resignation of CFO Kristi Matus is disappointing, but the reasons for her departure seem somewhat understandable, in our view (potentially viewed bifurcation of CFO/CAO role as a demotion). We think incoming CFO Karl Stubelis is very strong and should provide helpful continuity, both internally and externally (currently serves as Controller and previously as acting CFO). Finally, the CFO change does not change our positive long-term thesi

Top 10 Medical Stocks To Invest In Right Now: Transdigm Group Incorporated(TDG)

Advisors’ Opinion:

  • [By Mitchell Clark]

     This firm is not a household name. This Cleveland-based company, in the aerospace parts business, has approximately $12.0 billion in market capitalization on the stock market.

    TransDigm Group Incorporated (NYSE:TDG) doesn’t pay a regular dividend, but often pays out one-time, special dividends. In the past, they’ve been pretty hefty.

    Selling pumps, motors, power systems, and basically anything you can image that’s part of an aircraft, TDG’s been growing its financial results at a good clip.

  • [By Ben Levisohn]

    TransDigm Group (TDG) soared to the top of the S&P 500 today after beating earnings and sales forecasts.

    Agence France-Presse/Getty Images

    TransDigm gained 6.5% to $245.88 today, while the S&P 500 finished little changed at2,293.08.

    TransDigm reported a profit of $2.57, beating forecasts for$2.47, on sales of $814 million, topping the Street consensus for $804.5 million.

    TransDigm’s market capitalization rose to $13.1 billion today from $12.3 billion yesterday.

  • [By Lee Jackson]

    Transdigm Group Inc. (NYSE: TDG) had a director at the company step in and buy stock in a big way last week. That director purchased a total of 91,000 shares of the stock at prices ranging from $247.16 to $247.89. The total for the trade came in near $22.7 million.The company designs, produces and supplies aircraft components in the United States. Its stock closed trading last Friday at $251.488.

Top 10 Medical Stocks To Invest In Right Now: National Oilwell Varco, Inc.(NOV)

Advisors’ Opinion:

  • [By Garrett Baldwin]

    The price of Bitcoin faced more pressure over the weekend. The downturn came on news that several major banks have banned the purchasing of Bitcoin with credit cards. Bank of America Corp. (NYSE: BAC), JPMorgan Chase & Co. (NYSE: JPM), and Citigroup Inc. (NYSE: C) have all banned cryptocurrency purchases since Friday. This means that the top five credit card issuers have now halted the practice. Bitcoin sat at $7,773 this morning.
    Janet Yellen is officially out of the Federal Reserve and will be heading to the Brookings Institution. Today, Jerome Powell will begin his first term at the helm of the U.S. central bank. Powell takes over at an interesting time for the U.S. economy. The central bank is expected to raise interest rates three times in 2017. In addition, Powell must manage a $4.5 trillion balance sheet that the Fed built up in the wake of last decade’s financial crisis.
    Gold prices saw a slight gain in pre-market hours. But those gains could surge as markets continue to face questions about inflation and a weaker U.S. dollar. Gold prices saw one of their biggest one-day declines in two months on Friday. Investors are looking at this as a solid entry point given price expectations from Money Morning Resource Specialist Peter Krauth. Peter expects that gold prices will reach $1,400 by the end of June and rise to as high as $1,500 by December.
    VideoMeet the Trading Expert Who Could Help Make You a Millionaire
    Crude oil prices slid in pre-market hours to a one-month low. TheWTI crude oil price todayfell 0.6%. Brent crude dropped 1.1%. Markets are growing increasingly fearful that rising U.S. production could spur an oversupply of the markets.
    Four Stocks to Watch Today: WFC, AVGO, QCOM, BMY
    Shares of Wells Fargo & Co. (NYSE: WFC) are off more than 8% this morning because the Fed has forced new sanctions on the bank that will limit its growth. The Fed’s consent order will see the bank change four members of its board of directors and

  • [By Jim Robertson]

    On Tuesday, our Elite Opportunity Pronewsletter suggestedgoing long on large cap oilfield equipment manufacturer and technology stock National-Oilwell Varco, Inc (NYSE: NOV):

  • [By Shauna O’Brien]

    Jefferies reported on Monday that it has lifted its price target on National-Oilwell Varco, Inc. (NOV).

    The firm has reaffirmed a “Buy” rating on NOV, and has raised the company’s price target from $84 to $91. This price target suggests a 14% increase from the stock’s current price of $78.24.

    Analyst Brad Handler noted that NOV’s weak margin will likely rebound in 2014 and the chances of a dividend increase are high.

    Looking forward, the firm has lifted its order estimates for FY2013 from $10.8 billion to $11.3 billion. FY2014 earnings estimates have been raised from $6.40 to $6.50 per share and FY2015 estimates have been increased from $7.65 to $7.95 per share.

    National-Oilwell Varco shares were up 76 cents, or 0.97% during pre-market trading Monday. The stock is up 14% YTD.

  • [By Tony Daltorio]

    But the best investment in this sector, according to Moors, is National Oilwell Varco Inc. (NYSE: NOV).

    He calls it the “one company that stands to benefit most directly from what is happening in the equipment sector.”

  • [By Lauren Pollock]

    Among the companies with shares expected to actively trade in Tuesday’s session are Applied Materials Inc.(AMAT), Red Hat Inc.(RHT) and National Oilwell Varco Inc.(NOV)

Top 10 Medical Stocks To Invest In Right Now: Molex Incorporated(MOLX)

Advisors’ Opinion:

  • [By Shauna O’Brien]

    Shares of electronic connector maker Molex Incorporated (MOLX) skyrocketed on Monday morning after reports that the company will be acquired by Koch Industries.

    Koch Industries has agreed to acquire Molex for a total of $7.2 billion. This deal will include all outstanding shares of the company’s Common Stock, Class A Common Stock and Class B Common Stock for $38.50 per share.

    The deal has been approved by the board of directors of both companies. Molex will continue to maintain its current management team and its current headquarters in Lisle, IL.

    Molex shares were up $9.15, or 31.17%, during Monday morning trading. The stock is up 41% YTD.